nabu.science
MethodologyAboutContact

 

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Impact Profile
Free · About 5 minutes
Report #NBU-761B2D93·Framework v5.9·Pipeline v0.4·Evaluated 08 Oct 2026·OECD: 3.2 Clinical medicine·Subfield: Radiology, Nuclear Medicine and Imaging·Basis: Full text·Type: Diagnostic accuracy study

The Dementias Platform UK PET/MR harmonisation and test-retest study: assessment of PET repeatability and reproducibility across the national network.

Markiewicz et al.Markiewicz, Thompson, Wardlaw et al.·2026·European journal of nuclear medicine and molecular imaging·10.1007/s00259-026-07885-4 ↗

Primary claim

CL values across 74 scans showed excellent test-retest agreement (ICC = 0.968), improving to 0.987 after exclusion of one attenuation correction related outlier.

Supported · direct repeatability estimates support the direction, though precision intervals and prospective power planning are absent
In brief

A useful national PET/MR repeatability study whose multi-site evidence is constrained by an unsupported claim of PET/CT comparability.

ReliabilityCaveats4 of 4 checks completeRead the 2 entries ↓
Possible — the claim's weakest requirement is that the effect exists at all. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.
Abstract

PURPOSE: Positron emission tomography combined with magnetic resonance imaging (PET/MR) has not yet achieved the level of adoption of PET/CT. This study aimed to harmonise PET imaging protocols across a national PET/MR network and to quantitatively assess whether PET/MR can achieve reliability comparable to PET/CT. While previous PET test-retest studies have demonstrated good repeatability, they have typically been limited to small cohorts or restricted site configurations. METHODS: We conducted a multi-site harmonisation and rigorous test-retest study across the network of eight PET/MR scanners. Thirty-seven healthy older participants (65-90 years) underwent harmonised one-hour amyloid PET/MR scans using either [[Formula: see text]F]flutemetamol or [[Formula: see text]F]florbetaben on two occasions. Retest scans were performed under conditions of same-site repeatability or multi-site reproducibility. Harmonised acquisition and reconstruction protocols were applied, and amyloid burden was quantified on the Centiloid (CL) scale. RESULTS: CL values across 74 scans showed excellent test-retest agreement (ICC = 0.968), improving to 0.987 after exclusion of one attenuation correction related outlier. Mean test-retest variability was 2.58%. No statistically significant differences were observed across repeatability versus reproducibility conditions, scanner types, or tracers. CL measurements were highly consistent with three independent blinded visual reads. CONCLUSION: This study demonstrates that harmonised PET/MR achieves high reliability comparable to PET/CT. Although the accuracy of attenuation maps requires checks, this study supports the use of PET/MR for quantitative amyloid imaging in research and therapeutic trials, and provides a valuable open resource of image and raw PET/MR data for further methodological development.

Key Claims

Primary finding · Supported

CL values across 74 scans showed excellent test-retest agreement (ICC = 0.968), improving to 0.987 after exclusion of one attenuation correction related outlier.

Possible — the claim's weakest requirement is that the effect exists at all. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.

direct repeatability estimates support the direction, though precision intervals and prospective power planning are absent

Abstract; Results, Test-retest Reproducibility; Figure 1
Quote verified
Secondary · Tentative

No statistically significant differences were observed across repeatability versus reproducibility conditions, scanner types, or tracers.

small uneven subgroups and non-significance cannot establish equivalence across conditions, vendors, or tracers

Abstract; Results, Site, Equipment and Tracer Effects
Quote verified
Secondary · Tentative

This study demonstrates that harmonised PET/MR achieves high reliability comparable to PET/CT.

the comparison is indirect because the study includes no head-to-head PET/CT arm

Abstract, Conclusion; Conclusion
Quote verified
Secondary · Supported

CL measurements were highly consistent with three independent blinded visual reads.

high agreement and kappa support the claim, with unexplained restriction from 74 to 72 scans

Abstract, Results; Results, Figure 4
Quote verified

Derived from the full evaluation — not a separate score.

Strengths · Limitations

Strengths

#contribution

Broad multi-site harmonisation design

The study implements common PET/MR acquisition and reconstruction procedures across eight sites, two vendors, and two amyloid tracers, including same-site and cross-site retest conditions.

↳ Methods, opening study-design paragraphs; Results, Table 2

#methodological rigour

Transparent primary repeatability reporting

The full-cohort ICC of 0.968 is reported alongside the post-exclusion ICC of 0.987, and the attenuation-map cause of the outlier is investigated rather than silently removed.

↳ Results, Test-retest Reproducibility; Figure 1; Discussion, attenuation-correction paragraph

#methodological rigour

Independent blinded visual assessment

Three trained readers were blinded to participant identity and test–retest status, with complete reader agreement and visual–quantitative agreement statistics reported.

↳ Methods, Visual Assessment; Results, Figures 1 and 4

Limitations

#positioning

PET/CT comparison exceeds the design

The Abstract and Conclusion claim reliability comparable to PET/CT, but the study contains no direct PET/CT arm and the Discussion explicitly acknowledges that absence.

↳ Abstract, Conclusion; Discussion, limitations paragraph

#methodological rigour

Subgroup equivalence is not established

Non-significant tests in small, uneven groups are used to describe consistency across conditions, scanners, sites, and tracers, without a prospective equivalence margin or precision target.

↳ Results, Table 2 and Figures 2–3; Discussion, paragraph 3

#reporting

Analysis counts remain unreconciled

The paper reports 74 scans overall but 72 in Figure 4, while the mixed model uses 36 participants rather than the 37 completed pairs. These differences are not explicitly reconciled.

↳ Abstract; Methods, Statistical Analysis; Results, Figure 4

Does this match your read? Add your assessment ↓

Nabu Commentary

The eight-site, two-vendor design and transparent reporting of the attenuation-correction outlier support a useful network-level repeatability contribution. The primary ICC and TRV findings are credible for healthy older volunteers, but small subgroup cells, long and variable retest intervals, and absent precision planning limit claims of consistency across scanners, sites, and tracers. The main downward adjustment arises from the unqualified PET/CT-comparability claim, which is not identified by a direct comparator and conflicts with the limitation acknowledged in the Discussion. The study therefore supports conditional research use more securely than broad therapeutic-trial readiness.

Evaluate another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Evidence Score

Out of 5
012345
3.3±0.2

Contribution
3.8

The eight-site, two-vendor, two-tracer design adds network-level PET/MR repeatability and reproducibility evidence beyond smaller or more restricted prior studies. The advance remains bounded by 37 healthy participants and small condition-specific groups.

Methods, opening paragraphs and Participants; Results, Table 2

“across all eight DPUK sites equipped with hybrid PET/MR scanners”

Methodological Rigour
3.2

Randomised retest allocation, harmonised acquisition, Centiloid processing, Bland–Altman analysis, and blinded multi-reader assessment support the primary repeatability estimate. No prospective precision target or ICC confidence interval is reported, retest intervals extend to 482 days, and small subgroup tests are interpreted too strongly.

Methods, Statistical Analysis; Table 1; Results, Figures 1–3

“63.19 (112.59) [2–482]”

Reporting
3.2

The study design and principal ICC and TRV results are readily traceable, but the headline PET/CT comparison is stronger than the indirect evidence permits. Unexplained 74-versus-72 scan accounting and 37-versus-36 participant accounting further reduce reporting precision.

Abstract; Methods, Statistical Analysis; Results, Figure 4; Conclusion

“harmonised PET/MR achieves high reliability comparable to PET/CT”

Positioning
2.8

The Discussion substantively compares prior test–retest studies and acknowledges attenuation correction, population, tracer, and reconstruction limitations. Its admission that no direct PET/CT comparison was performed conflicts with the unqualified PET/CT-comparability conclusion, binding the Positioning score at 2.8.

Discussion, prior-study comparison and limitations paragraphs; Conclusion

“the absence of a direct head-to-head comparison with PET/CT”

Reliability

Caveats4 of 4 checks


Results checkClean

The reported numbers and statistics are consistent with the stated results.

Reporting and transparencyNoted

The visual-agreement analysis does not explicitly reconcile its 72 scans with the 74-scan cohort; the visual-read test has an unexplained factor-label/df mismatch; and data-access wording differs between controlled access and open availability.

Conflict of interest: not stated · Ethics approval: declared · Preregistration: not stated · Data availability: declared · Code availability: declared

Reference IntegrityNoted

48 references in manuscript 48 of 48 checkable references found in an index the reference list may be incompletely parsed; counts are indicative

References not verified automatically are resolved manually within 24 hours.

Post-Publication RecordClean

No retraction or expression of concern found in Crossref (includes Retraction Watch).

Last checked: 17 Oct 2026

Sources: Crossref (incl. Retraction Watch) ✓

Impact Profile

Impact areaHealth · Neurological · Alzheimer's disease and other dementias
Type of advanceEmpirical
Route to useSpecified
AdvanceExtends
BeneficiariesLarge
CitationsToo early
Policy · patentNot yet traced
ReachedNot reachedNot assessable or unverified
ReadinessPiloted
Foundational
Controlled
Piloted
Validated
Implementable
FoundationalImplementable

A single multi-site pilot in 37 healthy older volunteers showed the harmonised protocol working once, without independent confirmation or testing in symptomatic patient populations.

From the paper
“enable the inclusion of PET/MR scanners in multi-site clinical trials that rely on amyloid imaging for patient stratification, outcome assessment, and monitoring of therapeutic response”

The discussion names multi-site clinical trials as the setting and specifies including PET/MR scanners there for patient stratification, outcome assessment, and treatment-response monitoring.

Pathway

Trial sponsors and imaging units would adopt the harmonised PET/MR protocols and Centiloid quantification for amyloid-based patient stratification and treatment-response monitoring in multi-site dementia trials.

Barrier

MR-based attenuation map errors can corrupt Centiloid values, so stringent quality assurance is required, and evidence remains limited to healthy older participants without direct PET/CT comparison.

Evaluated 13 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. How Does Diagnostic Accuracy Evolve with Increased Breast MRI Experience?

    Wu, Alikhassi, Curpen · 2023 · Clinical medicine

    Primary claim

    Diagnostic accuracy improved exponentially with increased MRI experience (definition B, OR of 1.27 and 1.61 for 5 and 10 years, respectively, p = 0.03 for both).

    Tentative
    Evidence Score
    2.3±0.1
    Reliability
    Caveats
  2. General cognitive function and the brain's structural connectome

    Buchanan, Moodie, Batziou, et al. · 2026 · Basic medicine

    Primary claim

    g is supported by a widely distributed white matter network whose macroscopic wiring capacity, microstructural organisation, and age sensitivity contribute in distinct ways.

    Tentative
    Evidence Score
    3.6±0.2
    Reliability
    Caveats
  3. Fat signal suppression for coronary MRA at 3T using a water‐selective adiabatic T<sub>2</sub>‐preparation technique

    Andrew J. Coristine, Ruud B. van Heeswijk, Matthias Stuber · 2013 · Clinical medicine

    Primary claim

    The proposed WSA-T2-Prep method was shown to improve fat suppression and vessel sharpness as compared to a CA-T2-Prep technique

    Supported
    Evidence Score
    3.8±0.2
    Reliability
    Caveats

How the rubric works →